Skip to content

Azenta AZTA Capital investments accrued but not yet paid

Capital investments accrued but not yet paid at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO

Other financials

Income statement

See full
Revenue$144.8M+1.0%
Gross profit$62.0M-1.2%
Operating income-$165.8M-811%
Net income-$160.8M-237%
EPS (diluted)-$3.49-236%

Balance sheet

See full
Cash & equivalents$125.2M
Total debt$55.7M
Total equity$1.6B-8.3%
Total assets$1.9B

Cash flow

See full
Operating cash flow$13.5M-6.2%
CapEx$7.4M-0.1%
Free cash flow$6.1M-12.7%

Valuation

See full
Market cap$1.1B-16.3%
Enterprise value$1.03B
P/S1.8×-0.2×

Profitability

See full
Gross margin40%-1.0pp
Operating margin-31.6%-59.7pp
Net margin-29.1%-80.7pp
FCF margin8.6%

Returns & leverage

See full
Return on equity-10.7%-22.4pp
Debt / equity
Current ratio2.8×

Where this comes from

Reported directly by Azenta in its filing.

Tagged under the XBRL concept us-gaap:CapitalExpendituresIncurredButNotYetPaid.

The official record: Azenta’s 10-Q, filed February 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Azenta's capital investments accrued but not yet paid.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Azenta's capital investments accrued but not yet paid?
Azenta (AZTA) reported capital investments accrued but not yet paid of $5.7M in Q4 2025.
How has Azenta's capital investments accrued but not yet paid changed year-over-year?
Azenta's capital investments accrued but not yet paid increased by 75.5% year-over-year, from $3.25M to $5.7M.
What is the long-term trend for Azenta's capital investments accrued but not yet paid?
Over 2 years (2022 to 2024), Azenta's capital investments accrued but not yet paid has grown at a -47.9% compound annual growth rate (CAGR), from $10.2M to $2.77M.